PDEX
Pro-Dex, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$73.41
+18.88%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 77.5M | 77.5M | 66.6M | 53.8M | 46.1M |
| Cost of Revenue | 53.2M | 53.2M | 47.1M | 39.3M | 33.3M |
| Gross Profit | 24.3M | 24.3M | 19.5M | 14.6M | 12.7M |
| Operating Expenses | |||||
| R&D Expense | 3.3M | 3.3M | 3.6M | 3.2M | 2.8M |
| SG&A Expense | 8.0M | 8.0M | 5.2M | 4.2M | 4.2M |
| General & Admin Expense | 11.3M | — | 4.8M | 4.1M | 4.0M |
| Selling & Marketing Expense | 224.0K | — | 344.0K | 117.0K | 155.0K |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 11.3M | 11.3M | 8.8M | 7.4M | 7.0M |
| Cost and Expenses | 64.6M | 64.6M | 55.9M | 46.7M | 40.3M |
| Operating Income (EBIT) | 13.0M | 13.0M | 10.7M | 7.2M | 5.8M |
| Non-Operating | |||||
| Interest Income | 201.0K | — | 82.0K | 144.0K | 294.0K |
| Interest Expense | 1.4M | (812.0K) | 829.0K | 558.0K | 533.0K |
| Net Interest Income | (415.0K) | — | (747.0K) | (414.0K) | (239.0K) |
| Other Non-Op Income/Expense | 5.0M | 5.0M | 1.4M | (4.5M) | 3.7M |
| Non-Operating Income (excl Interest) | (12.0M) | — | (2.2M) | 4.0M | (4.2M) |
| EBT (Pre-Tax Income) | 18.0M | 18.0M | 12.1M | 2.6M | 9.4M |
| Income Tax Expense | (4.4M) | (4.4M) | 3.1M | 507.0K | 2.4M |
| Bottom Line | |||||
| Net Income | 13.7M | 13.7M | 9.0M | 2.1M | 7.1M |
| Earnings from Cont. Ops | 13.7M | 13.7M | 9.0M | 2.1M | 7.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 13.7M | 13.7M | 9.0M | 2.1M | 7.1M |
| Per Share | |||||
| Basic EPS | $4.22 | $4.24 | $2.73 | $0.61 | $1.98 |
| Diluted EPS | $4.12 | $4.12 | $2.67 | $0.60 | $1.95 |
| Revenue Per Share | $24.04 | $24.04 | $20.25 | $15.39 | $12.91 |
| Shares | |||||
| Basic Shares Outstanding | 3.2M | 3.2M | 3.3M | 3.5M | 3.6M |
| Diluted Shares Outstanding | 3.3M | 3.3M | 3.4M | 3.6M | 3.6M |
| Profitability Metrics | |||||
| EBITDA | 13.0M | 13.0M | 14.1M | 4.4M | 10.8M |
| D&A | 1.9M | — | 1.2M | 1.2M | 857.0K |
| EBIT | 15.0M | — | 12.9M | 3.2M | 10.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026